Literature DB >> 10627779

Mood disorders in patients after treatment for primary intracranial tumours.

S I Anderson1, R Taylor, I R Whittle.   

Abstract

The frequency of mood disorder was studied in a cohort of patients with treated intracranial glioma or meningioma, where psychological morbidity was related to physical and neuropsychological functioning and to the patients' knowledge of their disease. Forty patients were assessed on a range of physical, psychological and neuropsychological measures, with additional interview of a relative to obtain supplementary information regarding each patients' knowledge of their disease. Two (5%) of the 40 patients had clinically significant levels of anxiety, six (15%) clinically significant levels of depression and 92% full or intermediate knowledge about their prognosis. Psychological morbidity was associated with high levels of physical disability and also with cognitive dysfunction, but was not related to the grade of the patient's tumour or the extent to which the patient was aware of the nature of his or her disease. A proportion of patients with intracranial tumours suffer levels of psychological distress sufficient to warrant psychological and/or pharmacological intervention.

Entities:  

Mesh:

Year:  1999        PMID: 10627779

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  26 in total

1.  The use of a simple Likert scale to measure quality of life in brain tumor patients.

Authors:  M P Rogers; J Orav; P M Black
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  The course of neurocognitive functioning in high-grade glioma patients.

Authors:  Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

3.  Prognostic awareness and communication preferences among caregivers of patients with malignant glioma.

Authors:  A J Applebaum; K Buda; M Kryza-Lacombe; J J Buthorn; R Walker; K M Shaffer; T A D'Agostino; E L Diamond
Journal:  Psychooncology       Date:  2017-12-19       Impact factor: 3.894

4.  Are preoperative sex-related differences of affective symptoms in primary brain tumor patients associated with postoperative histopathological grading?

Authors:  Andre Richter; J Jenewein; N Krayenbühl; C Woernle; D Bellut
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

5.  Effect of Comorbid Depression on Surgical Outcomes After Craniotomy for Malignant Brain Tumors: A Nationwide Readmission Database Analysis.

Authors:  Kavelin Rumalla; Michelle Lin; Elliot Orloff; Li Ding; Gabriel Zada; William Mack; Frank Attenello
Journal:  World Neurosurg       Date:  2020-07-16       Impact factor: 2.104

6.  Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma.

Authors:  Ann M Maddrey; Jon A Bergeron; Elizabeth R Lombardo; Noelle K McDonald; Arlynn F Mulne; Paul D Barenberg; Daniel C Bowers
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

7.  A survey of disclosure of diagnosis to patients with glioma in Japan.

Authors:  Fukuko Yamamoto; Naoya Hashimoto; Naoki Kagawa; Yoshiko Okita; Yasuyoshi Chiba; Noriyuki Kijima; Manabu Kinoshita; Kikuko Yoshizu; Yasunori Fujimoto; Kei Hirai; Toshiki Yoshimine
Journal:  Int J Clin Oncol       Date:  2010-12-08       Impact factor: 3.402

Review 8.  Depression screening in patients with brain tumors: a review.

Authors:  Aiste Pranckeviciene; Adomas Bunevicius
Journal:  CNS Oncol       Date:  2015

Review 9.  The relationships between depression and brain tumors.

Authors:  N Scott Litofsky; Andrew G Resnick
Journal:  J Neurooncol       Date:  2009-03-05       Impact factor: 4.130

Review 10.  Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review.

Authors:  Eli L Diamond; Geoffrey W Corner; Antonio De Rosa; William Breitbart; Allison J Applebaum
Journal:  J Neurooncol       Date:  2014-05-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.